Via Oncology Launches Expanded Support for CMMI OCM Practices

Share Article

Via Pathways and Via Portal have been expanded to support key components for success in the Oncology Care Model from the Centers for Medicare and Medicaid Innovation.

Via Oncology Logo
Via Pathways have been essential to our success in transforming to value-based care, and their expansion into broader medical home tools will help us deliver patient-centric care in the most appropriate care setting.

Via Oncology (VIA) announced today that its Via Pathways and Via Portal have been expanded to support the key components for success in the Oncology Care Model (OCM) from the Centers for Medicare and Medicaid Innovation (CMMI). Items in this expansion include the ability to generate a treatment plan at the initiation of therapy and a survivorship plan after completion of therapy, both of which are pre-populated with data from the Via Portal such as staging, histology, biomarkers, treatment intent and treatment details.

Further supporting the OCM, VIA has incorporated regimen level information for patients to include risks of treatment, likely benefits of treatment, and overall prognosis for the disease. VIA has also expanded support for many required data collection and quality reporting needs on a customer-specific basis. Finally, VIA’s symptom assessment, adjudication, and treatment pathways will be available in a nurse triage and follow-up tool in September 2016.

“Via Pathways have been essential to our success in transforming to value-based care, and their expansion into broader medical home tools will help us deliver patient-centric care in the most appropriate care setting,” said Dr. Natalie Dickson, CMO at Tennessee Oncology, a large community-based practice.

Earlier this year, VIA successfully completed beta testing of a nurse triage module that will launch this fall to help providers better manage symptom-related patient calls and direct care to the most appropriate setting. Alongside that release, VIA will launch its proprietary Regimen Cost Estimator tool, which can be used for shared decision-making with patients and to provide the estimated total and patient cost for the treatment plan document.

“We’re excited to be able to support practices in the OCM model through not only adherence to evidence-based treatment but also the full range of oncology care,” said Kathy Lokay, CEO of Via Oncology.

In addition to clinical pathways for chemotherapy and biologic IV treatments, VIA provides physicians with evidence-based guidance for oral drugs, work-up, precision testing, symptom management, surveillance, and advance care planning. Additionally, radiation and surgical pathway content are accessible to medical oncologists as a tool to review appropriateness of care from other specialists treating their OCM patients.

Automated real-time emails can be sent securely to other physicians or staff based on virtually any data within the Via Portal including completion of adjuvant therapy for activating a survivorship visit. Practice reporting needs are supported by the ability to add mandatory questions such as treatment intent, discussion with patient, or performance status.

To learn more about Via Oncology’s full suite of value-based solutions, visit http://www.viaoncology.com or email sales(at)viaoncology(dot)com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Kathy Lokay
Via Oncology
+1 412-204-1052
Email >
@viaoncology
Follow >
Visit website